Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is multi-center, randomized, double-blind, placebo-controlled study to assess the
safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of
patients with mild to moderate COVID-19. This is a phase 2 study of cysteamine-pantetheine
disulfide (TTI-0102), an antiviral, anti-infectious, antioxidant and anti-CRS (cytokine
release syndrome) investigational drug. Subjects will be randomized 2:1 to receive TTI-0102
or placebo daily for up to 14 days. Up to 5 centers in the US and Canada will conduct this
study. 60 patients will be enrolled.